跳至主要内容
临床试验/NCT05144542
NCT05144542进行中(未招募)不适用

The Potential Risks and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer

M.D. Anderson Cancer Center1 个研究点 分布在 1 个国家目标入组 135 人开始时间: 2022年3月7日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
135
试验地点
1
主要终点
Cigarettes per day

研究概览

简要总结

This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer. E-cigarettes use heated vapor to deliver nicotine. Information gained from this trial may help inform regulators of the potential risks and benefits of switching smokers at high risk for lung cancer to electronic cigarettes. This research also may help inform the Food and Drug Administration (FDA) how best to regulate e-cigarettes with the goal of improving public health.

详细描述

PRIMARY OBJECTIVE:

I. To characterize the effects of switching from combustible cigarettes (CCs) to e-cigarettes (ECs) on product use, product acceptability, and reinforcement among adult daily CC smokers at high risk for lung cancer.

EXPLORATORY OBJECTIVES:

I. To characterize the effects of switching from CCs to ECs on biomarkers of inflammation and oxidative stress among adult daily CC smokers at high for lung cancer.

II. To characterize metabolomic changes that result from switching from CCs to ECs among CC smokers at high risk for lung cancer

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 50-80 years who currently smokes at least 1 or more combustible cigarettes per day OR who is a nondaily smoker (any self-reported smoking in the past 30 days) with a 20 pack-year history.
  • Being interested in trying ECs to change CC smoking behavior
  • Willing to have biospecimen samples taken, either in-home using a mobile phlebotomoty service, or at an approved collection site
  • Have an address where he/she can receive mail
  • Being fluent in spoken and written English
  • Agrees to comply with all MD Anderson institutional policies related to COVID-19 screening prior to any in-person research visit.
  • The individual agrees to not engage in study procedures or interactions with study personnel while operating a vehicle.

排除标准

  • Individuals who report depressive symptoms in the moderately severe or severe range on the PHQ-9 (scores of 15 or above); or who report current suicidal ideation on the PHQ-9
  • Have ever had a diagnosis of lung cancer, have uncontrolled or unstable medical condition (e.g., uncontrolled hypertension, angina, diabetes)
  • Unwilling to consent for blood draw
  • Evidence of cognitive deficits or instability that would preclude reliable study participation
  • Being pregnant, engaging in breast-feeding, or being of childbearing potential and engaging in sexual activity that could lead to pregnancy and is not protected by a medically acceptable, effective method of birth control while enrolled in the study, as determined by self-report. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use.
  • Considered by the investigator to be an unsuitable or unstable candidate (including but not limited to the following situations: unwilling or unable to comply with study procedures)
  • Individuals who reside in an area that is outside of our shipping company or mobile phlebotomty contractors' areas of operation or in a jurisdiction outside of our medical staff's licensure (if unable to attend in-person clinic visits) AND who decline to come in to clinic to provide necessary samples and/or collect study products.

研究组 & 干预措施

E-Cigarettes

Experimental

Participants vape study-provided e-cigarettes for 26 weeks. Participants use smartphone to answer questions about nicotine cravings and mood and log daily smoking activity every day for up to 26 weeks. Participants complete questionnaires over 30-45 minutes and undergo collection of urine and blood samples on study.

干预措施: Nicotine Replacement (Drug)

结局指标

主要结局

Cigarettes per day

时间窗: Up to 182 days

Will be collected using smartphone daily diary data of combustible cigarette use over last 24 hours.

Combustible Cigarettes Per Day

时间窗: Study Week 1 and Week 27

Mean cigarettes per day during the week of baseline combustible cigarette smoking and during the final week of electronic cigarette provision (week 27)

次要结局

  • High-sensitivity C-reactive protein (hs-CRP)(through study completion, an average of 1 year)
  • White blood cells (WBC)(through study completion, an average of 1 year)
  • 8-epi prostaglandin F2 alpha (8-epi-PGF2a)(through study completion, an average of 1 year)
  • Electronic Cigarette Sessions Per Day(Study Week 27)
  • Anabasine(Study Week 1 and Week 27)
  • Fagerström Test for Cigarette Dependence(Study Week 1 and Week 27)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
早期 1 期
Electronic Cigarette-derived Oxidants and Cardiopulmonary EffectsChronic Obstructive Pulmonary Disease
NCT05239793Milton S. Hershey Medical Center30
已完成
不适用
Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment FailuresSmoking, Cigarette
NCT03502200Ohio State University Comprehensive Cancer Center350
已完成
不适用
Effects of Electronic Cigarette Use on the LungsCurrent SmokerNever SmokerTobacco Use DisorderFormer SmokerE-cig User
NCT02596685Ohio State University Comprehensive Cancer Center142
撤回
不适用
Cigarette Harm Reduction With Electronic Cigarette UseNicotine DependenceTobacco ToxicityNicotine Dependence, CigarettesCardiovascular Risk FactorNicotine Withdrawal
NCT03473483University of California, San Francisco
撤回
不适用
Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and LungHead and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaStage I Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage I Lung Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
NCT05412875Ohio State University Comprehensive Cancer Center